rbs rating

fyi, RBS kept ACL's buy rating and target this morning as:

RBS Australia rates ACL as Buy (1) -
Here's one for the short term traders: RBS analysts highlight FDA approval times for generic drugs eligible for priority review now average about 13 months. Given Alchemia's lead product was accepted for review in May 2009, approval of its generic fondaparinux should thus be imminent.

Buy rating remains in place, as does the $0.86 price target.

Target price is $0.86 Current Price is $0.51 Difference: $0.355
If ACL meets the RBS Australia target it will return approximately 70% (excluding dividends, fees and charges)